DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Funds an early, hypothesis-driven ALS drug or therapy idea before there's data proving it will work.
Most ALS therapeutic ideas die for a boring reason: nobody will fund the very first, riskiest test of whether they're worth pursuing at all. This award exists for exactly that gap.
What's funded is early, hypothesis-driven drug or therapy discovery work, aimed at generating the preliminary data that opens up a future line of therapeutic investigation — not a therapy that's already validated.
The…
Early, hypothesis-driven ALS drug or therapy discovery work generating preliminary data for future therapeutic investigation, judged on the strength of the approach rather than on existing preliminary data — an interpretable result without supporting preliminary data is an acceptable outcome. No clinical trial or Community Collaboration requirement applies.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up